摘要
目的研究胃食管反流病患者实行莫沙必利+雷贝拉唑治疗效果。方法选择2018年1月—2020年1月门诊治疗的86例胃食管反流病患者,采纳随机数字表法分观察组(莫沙必利+雷贝拉唑)与对照组(莫沙必利)各43例,两组的临床疗效比较。结果治疗前比较两组肠胃激素水平无统计学差异(P>0.05);治疗后与对照组比较,观察组血浆胃动素、血清胃泌素指标较高;观察组有效率(95.35%)高于对照组(53.49%),χ^2=5.7794,P=0.0162,具统计学意义(P<0.05)。结论莫沙必利+雷贝拉唑治疗能提高消化内科胃食管反流病患者整体疗效、稳定病情,改善身体不适、加速疾病康复进程,值得推崇。
Objective To study the effect of mosapride+rabeprazole in patients with gastroesophageal reflux disease.Methods Eighty-six patients with gastroesophageal reflux disease treated in outpatient clinics from January 2018 to January 2020 were selected and divided into observation group(mosapride+rabeprazole)and control group(mosapride)by random number table.)and 43 cases in each group,the clinical efficacy of the two groups was compared.Results There was no significant difference in the levels of gastrointestinal hormones between the two groups before treatment(P>0.05);after treatment,compared with the control group,the observation group had higher plasma motilin and serum gastrin indexes;the observation group had a higher effective rate(95.35%)In the control group(53.49%),χ^2=5.7794,P=0.0162,which was statistically significant(P<0.05).Conclusion Mosapride+rabeprazole treatment can improve the overall curative effect of patients with gastroesophageal reflux disease in the department of gastroenterology,stabilize the condition,improve physical discomfort,and accelerate the recovery of the disease.It is worthy of praise.
作者
朱丽娟
ZHU Lijuan(Department of Internal Medicine,Guanlin Hospital,Yixing City,Jiangsu Province,Yixing Jiangsu 214251,China)
出处
《中国卫生标准管理》
2020年第24期113-115,共3页
China Health Standard Management
